ProText Mobility, Inc. (TXTM)
USD 0.0
(-11.11%)
USD 0.0
(-11.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -54.27 Thousand USD | -110.33% |
| 2022 | 525.15 Thousand USD | 469.08% |
| 2021 | -142.28 Thousand USD | 71.88% |
| 2020 | -506.03 Thousand USD | 66.34% |
| 2019 | -1.5 Million USD | -192.98% |
| 2018 | -513.13 Thousand USD | 6.47% |
| 2017 | -548.6 Thousand USD | -88.91% |
| 2016 | -290.4 Thousand USD | 0.0% |
| 2013 | -1.44 Million USD | 33.29% |
| 2012 | -2.16 Million USD | 39.54% |
| 2011 | -3.58 Million USD | 36.81% |
| 2010 | -5.67 Million USD | -26.74% |
| 2009 | -4.48 Million USD | 13.66% |
| 2008 | -5.19 Million USD | 17.15% |
| 2007 | -6.26 Million USD | -58.52% |
| 2006 | -3.95 Million USD | -4.53% |
| 2005 | -3.78 Million USD | -182.49% |
| 2004 | -1.33 Million USD | -25.25% |
| 2003 | -1.06 Million USD | -79.67% |
| 2002 | -594.67 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -5270.00 USD | 73.71% |
| 2024 Q1 | -20.04 Thousand USD | -240.45% |
| 2023 Q3 | -6923.00 USD | 73.45% |
| 2023 Q4 | -5889.00 USD | 14.94% |
| 2023 FY | -54.27 Thousand USD | -110.33% |
| 2023 Q1 | -15.39 Thousand USD | -103.06% |
| 2023 Q2 | -26.07 Thousand USD | -69.4% |
| 2022 Q2 | 74.34 Thousand USD | 243.23% |
| 2022 FY | 525.15 Thousand USD | 469.08% |
| 2022 Q1 | -51.9 Thousand USD | -43.9% |
| 2022 Q3 | -1242.00 USD | -101.67% |
| 2022 Q4 | 503.3 Thousand USD | 40623.83% |
| 2021 Q3 | -38.07 Thousand USD | -11.74% |
| 2021 Q1 | -34.07 Thousand USD | 0.0% |
| 2021 FY | -142.28 Thousand USD | 71.88% |
| 2021 Q2 | -34.07 Thousand USD | 0.0% |
| 2021 Q4 | -36.07 Thousand USD | 5.25% |
| 2020 FY | -506.03 Thousand USD | 66.34% |
| 2019 FY | -1.5 Million USD | -192.98% |
| 2018 FY | -513.13 Thousand USD | 6.47% |
| 2017 FY | -548.6 Thousand USD | -88.91% |
| 2016 FY | -290.4 Thousand USD | 0.0% |
| 2014 Q1 | -428.76 Thousand USD | -33.1% |
| 2014 Q3 | -293.73 Thousand USD | 57.93% |
| 2014 Q2 | -698.29 Thousand USD | -62.86% |
| 2013 Q1 | -337.59 Thousand USD | 41.35% |
| 2013 FY | -1.44 Million USD | 33.29% |
| 2013 Q4 | -322.14 Thousand USD | 24.65% |
| 2013 Q2 | -360.12 Thousand USD | -6.67% |
| 2013 Q3 | -427.52 Thousand USD | -18.72% |
| 2012 Q1 | -555.25 Thousand USD | 43.13% |
| 2012 Q3 | -448.55 Thousand USD | 26.8% |
| 2012 FY | -2.16 Million USD | 39.54% |
| 2012 Q4 | -575.63 Thousand USD | -28.33% |
| 2012 Q2 | -612.79 Thousand USD | -10.36% |
| 2011 Q1 | -1.37 Million USD | 27.31% |
| 2011 Q2 | -580.21 Thousand USD | 57.82% |
| 2011 Q3 | -656.54 Thousand USD | -13.16% |
| 2011 Q4 | -976.39 Thousand USD | -48.72% |
| 2011 FY | -3.58 Million USD | 36.81% |
| 2010 Q2 | -1.49 Million USD | -32.22% |
| 2010 FY | -5.67 Million USD | -26.74% |
| 2010 Q4 | -1.89 Million USD | -62.31% |
| 2010 Q3 | -1.16 Million USD | 21.86% |
| 2010 Q1 | -1.12 Million USD | 6.38% |
| 2009 Q4 | -1.2 Million USD | 12.92% |
| 2009 FY | -4.48 Million USD | 13.66% |
| 2009 Q1 | -1.05 Million USD | 77.15% |
| 2009 Q2 | -839.02 Thousand USD | 20.27% |
| 2009 Q3 | -1.38 Million USD | -64.98% |
| 2008 FY | -5.19 Million USD | 17.15% |
| 2008 Q4 | -4.6 Million USD | -75.53% |
| 2008 Q3 | -2.62 Million USD | -129.86% |
| 2008 Q2 | -1.14 Million USD | -27.2% |
| 2008 Q1 | -897.27 Thousand USD | 65.07% |
| 2007 Q4 | -2.56 Million USD | -132.28% |
| 2007 FY | -6.26 Million USD | -58.52% |
| 2007 Q2 | -1.42 Million USD | -21.46% |
| 2007 Q1 | -1.16 Million USD | -11.9% |
| 2007 Q3 | -1.1 Million USD | 22.14% |
| 2006 Q3 | -972.46 Thousand USD | -5.32% |
| 2006 FY | -3.95 Million USD | -4.53% |
| 2006 Q2 | -923.31 Thousand USD | 29.28% |
| 2006 Q1 | -1.3 Million USD | 53.4% |
| 2006 Q4 | -1.04 Million USD | -7.46% |
| 2005 Q2 | -355.71 Thousand USD | 25.35% |
| 2005 FY | -3.78 Million USD | -182.49% |
| 2005 Q1 | -476.51 Thousand USD | -12.81% |
| 2005 Q3 | -330.55 Thousand USD | 7.07% |
| 2005 Q4 | -2.8 Million USD | -747.52% |
| 2004 FY | -1.33 Million USD | -25.25% |
| 2004 Q2 | -329.22 Thousand USD | -5.87% |
| 2004 Q3 | -275.62 Thousand USD | 16.28% |
| 2004 Q1 | -310.98 Thousand USD | 35.33% |
| 2004 Q4 | -422.39 Thousand USD | -53.25% |
| 2003 Q1 | -245.8 Thousand USD | 0.0% |
| 2003 FY | -1.06 Million USD | -79.67% |
| 2003 Q4 | -480.89 Thousand USD | -348.26% |
| 2003 Q3 | -107.28 Thousand USD | 54.24% |
| 2003 Q2 | -234.46 Thousand USD | 4.61% |
| 2002 FY | -594.67 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 95.936% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 99.223% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.102% |
| Nascent Biotech, Inc. | -2.08 Million USD | 97.4% |
| Rebus Holdings, Inc. | -1.02 Million USD | 94.679% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.083% |
| Qrons Inc. | -789.34 Thousand USD | 93.124% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 91.418% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.913% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 86.937% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.856% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.928% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 99.175% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 80.149% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.932% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 98.124% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 97.019% |
| Mesoblast Limited | -87.95 Million USD | 99.938% |
| Marizyme, Inc. | -65.34 Million USD | 99.917% |
| Genus plc | 7.9 Million USD | 100.687% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 99.502% |
| Pharming Group N.V. | -10.54 Million USD | 99.485% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 97.499% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 98.537% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 99.386% |
| ContraFect Corporation | -65.15 Million USD | 99.917% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 98.889% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 96.858% |
| IMV Inc. | -36.48 Million USD | 99.851% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 99.327% |
| MultiCell Technologies, Inc. | -380.07 USD | -14179.475% |
| ONE Bio Corp. | 8.67 Million USD | 100.625% |
| Accustem Sciences Inc. | -3.74 Million USD | 98.551% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.895% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 95.717% |
| Q BioMed Inc. | -2.05 Million USD | 97.355% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 98.546% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 97.72% |
| Biomind Labs Inc. | -1.21 Million USD | 95.531% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.909% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 98.25% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 99.313% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 97.216% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -262.393% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 99.658% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 99.067% |
| GB Sciences, Inc. | -1.36 Million USD | 96.014% |
| Alpha Cognition Inc. | -13.77 Million USD | 99.606% |
| HST Global, Inc. | -146.21 Thousand USD | 62.881% |
| CSL Limited | 2.64 Billion USD | 100.002% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 96.907% |
| Halberd Corporation | -79.67 Thousand USD | 31.884% |
| Enzolytics Inc. | -2.17 Million USD | 97.507% |
| Agentix Corp. | -1.37 Million USD | 96.051% |
| Resverlogix Corp. | -3.61 Million USD | 98.497% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 98.289% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.982% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 155.38% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 100.784% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 98.634% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 98.207% |
| AVAX Technologies, Inc. | -6.41 Million USD | 99.154% |
| Zenith Capital Corp. | -10.59 Million USD | 99.488% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.943% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -133.508% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 98.691% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 10.206% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 97.293% |
| Kadimastem Ltd | -3.3 Million USD | 98.359% |
| Helix BioMedix, Inc. | -1.05 Million USD | 94.861% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 98.579% |
| BioStem Technologies, Inc. | -8.48 Million USD | 99.36% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 87.704% |
| LadRx Corporation | 400.44 Thousand USD | 113.553% |
| Cell Source, Inc. | -5.32 Million USD | 98.98% |
| Regen BioPharma, Inc. | 1.02 Million USD | 105.303% |
| Regen BioPharma, Inc. | 1.02 Million USD | 105.303% |
| NovAccess Global Inc. | -4.76 Million USD | 98.862% |
| Affymax, Inc. | -14.42 Million USD | 99.624% |
| Itoco Inc. | -1.86 Million USD | 97.096% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 98.778% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 96.748% |
| Mobile Lads Corp. | -2.26 Million USD | 97.602% |
| CytoDyn Inc. | -49.84 Million USD | 99.891% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 31.33% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 76.21% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 94.236% |
| SYBLEU INC | -180.3 Thousand USD | 69.9% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 96.635% |
| International Stem Cell Corporation | -131 Thousand USD | 58.571% |
| Bioxytran, Inc. | -4.28 Million USD | 98.732% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 97.855% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.887% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 97.433% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 93.05% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 98.287% |
| Neutra Corp. | -233.46 Thousand USD | 76.754% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 99.733% |
| PureTech Health plc | -65.69 Million USD | 99.917% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 99.745% |
| IXICO plc | -1.17 Million USD | 95.393% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 99.453% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.905% |
| CSL Limited | 2.64 Billion USD | 100.002% |
| Cellectis S.A. | -103.17 Million USD | 99.947% |